OPTIMAL: A Multinational Phase III Study of Oral Paclitaxel (DHP107) versus Intravenous Weekly Paclitaxel in HER2-Negative Recurrent or Metastatic Breast Cancer - PubMed
4 hours ago
- #breast cancer
- #oral chemotherapy
- #paclitaxel
- The study compared oral paclitaxel (DHP107) with intravenous (IV) paclitaxel in HER2-negative recurrent or metastatic breast cancer.
- DHP107 showed non-inferior progression-free survival (PFS) compared to IV paclitaxel (10.0 vs. 8.5 months).
- Overall survival (OS) was similar between DHP107 (32.6 months) and IV paclitaxel (31.8 months).
- DHP107 had higher rates of neutropenia, febrile neutropenia, nausea, diarrhea, and vomiting.
- IV paclitaxel was associated with more peripheral neuropathy and hypersensitivity reactions.
- Quality of life (QoL) was comparable between both treatment groups.
- No treatment-related deaths occurred in the DHP107 group, while one occurred in the IV paclitaxel group.
- DHP107 is a viable and convenient alternative to IV paclitaxel for HER2-negative breast cancer.